Russell Investments Group
TGTX icon

Russell Investments Group’s TG Therapeutics TGTX Stock Holding History

Russell Investments Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Buy
301,315
+101,663
+51% +$4.16M 0.01% 818
2026
Q1 		$6.63M Sell
199,652
-5,330
-3% -$159K 0.01% 1186
2025
Q4 		$6.11M Buy
204,982
+20,756
+11% +$678K 0.01% 1185
2025
Q3 		$6.66M Sell
184,226
-164,257
-47% -$5.41M 0.01% 1136
2025
Q2 		$12.5M Buy
348,483
+196,269
+129% +$7.31M 0.02% 757
2025
Q1 		$6M Buy
152,214
+117,508
+339% +$3.95M 0.01% 1063
2024
Q4 		$1.04M Buy
34,706
+26,506
+323% +$761K ﹤0.01% 1996
2024
Q3 		$192K Sell
8,200
-45,056
-85% -$984K ﹤0.01% 2523
2024
Q2 		$947K Buy
53,256
+917
+2% +$14.6K ﹤0.01% 1996
2024
Q1 		$796K Buy
52,339
+29,923
+133% +$477K ﹤0.01% 2059
2023
Q4 		$383K Sell
22,416
-1,627
-7% -$18.9K ﹤0.01% 2298
2023
Q3 		$201K Buy
24,043
+20,061
+504% +$280K ﹤0.01% 2491
2023
Q2 		$98.9K Buy
3,982
+2,600
+188% +$67.2K ﹤0.01% 2604
2023
Q1 		$20.8K Sell
1,382
-29,271
-95% -$445K ﹤0.01% 2807
2022
Q4 		$363K Buy
30,653
+5,401
+21% +$39.2K ﹤0.01% 2397
2022
Q3 		$148K Buy
+25,252
New +$166K ﹤0.01% 2605
2022
Q2 		– Sell
-1,159
Closed -$11K – 2963
2022
Q1 		$11K Sell
1,159
-36,884
-97% -$427K ﹤0.01% 2707
2021
Q4 		$722K Sell
38,043
-9,826
-21% -$255K ﹤0.01% 2305
2021
Q3 		$1.59M Sell
47,869
-7,971
-14% -$247K ﹤0.01% 1954
2021
Q2 		$2.16M Sell
55,840
-33,110
-37% -$1.3M ﹤0.01% 1862
2021
Q1 		$4.29M Sell
88,950
-37,013
-29% -$1.78M 0.01% 1438
2020
Q4 		$6.55M Buy
125,963
+1,983
+2% +$67K 0.01% 1094
2020
Q3 		$3.31M Buy
123,980
+112,471
+977% +$2.59M 0.01% 1379
2020
Q2 		$224K Buy
+11,509
New +$185K ﹤0.01% 2680
2018
Q1 		– Sell
-13,209
Closed -$116K – 2995
2017
Q4 		$116K Hold
13,209
– – ﹤0.01% 2752
2017
Q3 		$157K Sell
13,209
-22,382
-63% -$255K ﹤0.01% 2712
2017
Q2 		$358K Sell
35,591
-33,969
-49% -$380K ﹤0.01% 2534
2017
Q1 		$811K Buy
+69,560
New +$499K ﹤0.01% 2216

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Russell Investments Group's TGTX Position: Q2 2026 in Review

Russell Investments Group increased its TG Therapeutics (TGTX) stake by 51% in Q2 2026, buying an estimated $4.16M and bringing the position to 301,315 shares worth $16.6M. The position accounts for 0.01% of the portfolio, ranked #818.

Russell Investments Group first reported a position in TGTX in Q1 2017 and has held it in 28 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Russell Investments Group held 301,315 shares of TG Therapeutics worth $16.6M as of Q2 2026.
  • Russell Investments Group bought 101,663 TG Therapeutics shares in Q2 2026, an estimated $4.16M.
  • TG Therapeutics made up 0.01% of Russell Investments Group's portfolio in Q2 2026, its #818 holding.
  • Russell Investments Group first reported a position in TG Therapeutics in Q1 2017 and has held it in 28 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.